AbbVie Inc. ABBV

NYSE US Health Care Biotechnology

$293.00 ▼ -0.10% ($-0.30)

Index member: S&P 500

Open $293.29

Prev Close $293.30

Day Range $291.04 – $294.43

52W Range $190.75 – $302.93

Market Cap $514.92B

P/E (TTM) 49.79

Beta 0.15

Div Yield 4.47%

EPS (TTM) $5.83

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NEW YORK STOCK EXCHANGE, INC.
Currency	USD
IPO Date	2013-01-02
Shares Out.	1,767,120,000
Website	abbvie.com/ ↗
Phone	13023513367
Employees	57,000
Revenue	$17.40B
Gross Profit	$13.12B
Net Income	$4.22B
Free Cash Flow	$18.87B
Total Assets	$147.68B
Total Liabilities	$152.22B
Equity	-$4.54B

About AbbVie Inc.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

AbbVie Inc. is a publicly traded company under the ticker symbol ABBV on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.